

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**21-870**

**MEDICAL REVIEW**

**DIVISION DIRECTOR'S SUMMARY MEMO TO FILE**

**DATE OF REVIEW:** August 19, 2005

**NDA:** 21-870

**DRUG:** Fludeoxyglucose F 18 Injection

**SUBMISSION DATE:** November 19, 2004

**USER FEE GOAL DATE:** September 19, 2005

**CATEGORY:** Original NDA

**SPONSOR:** North Shore/LIJ Research Institute

**RELATED DMF:** 16623; 10095

**REVIEW TEAM:** **Chemistry:** M. Salazar/E.Leutzinger  
**Microbiology:** J.McVey/D.Hussong  
**Project Mgt:** T.Nguyen

**BACKGROUND**

Under the current law [section 121(c)(2) of the Food and Drug Administration Modernization Act (FDAMA) and section 501(a)(2)(C) of the Federal Food, Drug, and Cosmetic Act], PET producers may continue to produce compounded PET drug products without FDA approval until two years after the date that the FDA completes its new approval procedures and current good manufacturing practice regulations for PET products, as long as the activities are within the meaning of the term "compounded positron emission tomography drug" and are in compliance with the USP General Chapter <823> titled "Radiopharmaceuticals for Positron Emission Tomography - Compounding" and any applicable USP monographs.

However, the PET provisions of FDAMA encourage voluntary submission of such applications. The North Shore/LIJ Research Institute has taken the initiative of seeking NDA approval at this time for Fludeoxyglucose F 18 Injection.

**SUMMARY**

The Federal Register Notice (FR) of March 10, 2000, states that there is sufficient information for the clinical and pre-clinical labeling of Fludeoxyglucose F 18 Injection for the indications listed in the FR Notice.

The NDA process has incorporated a chemistry review, microbiology review, and facility inspections.

### **CHEMISTRY REVIEW**

The primary chemistry review has been performed by Milagros Salazar, Ph.D. Her primary chemistry review has been concurred on the secondary review by the chemistry Team Leader, Eldon Leutzinger, Ph.D.

The chemistry review recommendations and conclusions for approvability are the following:

- The application is recommended for approval action for manufacturing and controls under section 505 of the Act.
- Foreign and domestic manufacturing facilities were inspected on April 11-15, and June 6 and 7, 2005, and have been determined to be in acceptable compliance with the currently applicable standards for PET drugs products (i.e., USP chapter <823>).
- No recommendations were given for Phase 4 (Post-Marketing) commitments, agreements and/or risk management steps.

### **MICROBIOLOGY REVIEW**

The microbiology review has been performed by James L. McVey, Ph.D., and his primary microbiology review has been concurred on the secondary review by the microbiology Team Leader, David Hussong, Ph.D.

The microbiology review recommendations and conclusions for approvability are the following:

- This submission is recommended for approval on the basis of product quality microbiology.
- No recommendations were given on Phase 4 commitments and/or agreements.

### **EXCLUSIVITY SUMMARY**

The Exclusivity Summary Checklist has been completed and this approval is for a single active ingredient product.

Previously approved under section 505 of the Act: NDA# 20-306 and NDA# 21-768: Fludeoxyglucose F 18 Injection.

## **PEDIATRIC PAGE**

As noted, each of the approved indications must have pediatric studies.

A deferral, based on too few children with disease to study, has been granted with a due date for completion of studies by August 19, 2015, for the following two indications:

1. In positron emission tomography (PET) imaging for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.
2. In positron emission tomography (PET) imaging in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging, for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function.

Pediatric studies have been completed for the third indication listed below:

3. In positron emission tomography (PET) imaging in patients for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.

## **DIVISION DIRECTOR'S SUMMARY COMMENTS**

- A. I concur with the chemistry and the microbiology review comments and recommendations as stated in these reviews.
- B. I concur with the pediatric study deferral for the stated two indications.
- C. I concur with the Exclusivity Summary.

## **REGULATORY ACTION**

- A. Approval, effective the date of the regulatory action letter for the stated three indications for use as recommended in the agreed-upon labeling text:
  1. In positron emission tomography (PET) imaging for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.

2. In positron emission tomography (PET) imaging in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging, for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function.
  3. In positron emission tomography (PET) imaging in patients for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.
- B. The deferred pediatric studies required under section 2 of the Pediatric Research Equity Act (PREA) are considered required post-marketing study commitments. The status summary of these post-marketing studies shall be reported annually according to 21 CFR 314.81, and should include expected summary completion and final report submission dates, any changes in plans since the last annual report.

George Q. Mills, M.D., M.B.A.  
Division Director  
Division Medical Imaging and Hematology Products, HFD-160  
Center for Drug Evaluation and Research  
Food and Drug Administration

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
George Mills  
8/19/2005 11:42:04 AM  
MEDICAL OFFICER